Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis

NCT ID: NCT06279065

Last Updated: 2024-05-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-29

Study Completion Date

2028-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients. At diagnosis and 6 month follow up we will analyze the oral, blood and gut microbiome from GCA patients and healthy controls. Thereby identified potential candidate biota will be further analyzed for possible interactions and influence on the immune system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Giant Cell Arteritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GCA Patients

Primary diagnosis of giant cell arteritis

Analysis of blood and microbiome samples (stool, oral lavage)

Intervention Type DIAGNOSTIC_TEST

Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells

Control

Control group without rheumatologic disease

Analysis of blood and microbiome samples (stool, oral lavage)

Intervention Type DIAGNOSTIC_TEST

Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Analysis of blood and microbiome samples (stool, oral lavage)

Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Diagnosis of Giant cell arteritis (only in one arm)

Exclusion Criteria

* chronic infection (viral, fungi, bacteria) including human immunodeficiency viruses, Hepatitis B/C
* acute infection with usage of antibiotics less then 90 days before screening
* major gastro-intestinal surgery \<5 years from screening
* gastro-intestinal bleeding \<90 days before screening
* inflammatory bowel disease (confirmed bioptically)
* bulimia or anorexia nervosa
* adipositas (body mass index ≥ 40)
* intake of high dosage of probiotics (\>10\^9 colony forming units per day) \<90 days before screening
* not controlled Diabetes mellitus
* Malignancy within one year (except for squamous skin - and basal skin carcinoma without metastasis, cervix carcinoma with curative surgery, Cutaneous T-cell lymphoma)
* known abuse of alcohol oder drugs.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Bonn

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Valentin Schäfer

Head of the rheumatology department, University Hospital Bonn

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinic of Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn

Bonn, North Rhine-Westphalia, Germany

Site Status RECRUITING

University Hospital Bonn

Bonn, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Valentin S. Schäfer, Dr. med.

Role: primary

+49 228 287-17000

Valentin Schäfer, MD

Role: primary

+28 287 17000

Maike Adamson

Role: backup

+28 287 17000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

373/23-EP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.